Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189).

被引：2
作者：
Inwards, David James
Hillman, David. W.
Fishkin, Paul A.
White, William L.
Morton, Roscoe F.
Dakhil, Shaker R.
Nikcevich, Daniel A.
Wender, Donald B.
Fitch, Tom R.
Kurtin, Paul J.
机构：
[1] Mayo Clin, Coll Med, Rochester, MN USA
[2] Illinois Oncol Res Assoc, Peoria, IL USA
[3] Med Oncol & Hematol Associates, Des Moines, IA USA
[4] Witchita CCOP, Wichita, KS USA
[5] Duluth Clin, Duluth, MN USA
[6] Siouxland Reg Canc Ctr, Sioux City, IA USA
[7] Mayo Clin Scottsdale, Scottsdale, AZ USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2746.2746
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2746
引用
收藏
页码：777A / 777A
页数：1
相关论文
共 50 条
  • [41] Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma
    Lee, Hun Ju
    Romaguera, Jorge E.
    Feng, Lei
    Desai, Aakash P.
    Zhang, Liang
    Fanale, Michelle
    Samaniego, Felipe
    Hagemeister, Fredrick B.
    Fayad, Luis E.
    Rodriguez, Maria A.
    Medeiros, Jeffrey L.
    Hartig, Kimberly
    Nomie, Krystle
    Ahmed, Makhdum
    Badillo, Maria
    Ye, Haige
    Oki, Yasuhiro
    Lin, Pei
    Nastoupil, Loretta
    Westin, Jason
    Wang, Michael
    ONCOLOGIST, 2017, 22 (05) : 549 - 553
  • [42] A randomised phase II study of fludarabine/cyclophosphamide +/-rituximab in patients with untreated mantle cell lymphoma
    Rule, S
    Burton, C
    Waleski, J
    Jack, A
    Seymour, J
    ANNALS OF ONCOLOGY, 2005, 16 : 95 - 95
  • [43] A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Luhua
    Fayad, Luis
    Hagemeister, Fredrick B.
    Neelapu, Sattva
    Samaniego, Felipe
    McLaughlin, Peter
    Samuels, Barry
    Yi, Qing
    Pro, Barbara
    Fanale, Michelle
    Shah, Jatin
    Younes, Anas
    Bell, Neda
    Knight, Robert
    Zeldis, Jerome B.
    Cabanillas, Fernando
    Kwak, Larry
    Romaguera, Jorge
    BLOOD, 2009, 114 (22) : 1064 - 1065
  • [44] Immunoglobulin recovery following high dose therapy,and post-ASCT rituximab for relapsed follicular Lymphoma(FL) and newly diagnosed mantle cell lymphoma (MCL) compared to standard dose chemotherapy +/- Rituximab®.
    Buckstein, RJ
    Mangel, J
    Imrie, KR
    Spaner, D
    Boudreau, A
    Crump, M
    Pao, J
    Foden, C
    Berinstein, N
    BLOOD, 2002, 100 (11) : 480B - 480B
  • [45] A Prospective Study of Rituximab/Bendamustine and Rituximab/DHAP plus /- Zanubrutinib Induction Therapy with or without ASCT in Young Newly Diagnosed Mantle Cell Lymphoma
    Wang, Hui
    Xing, Lijie
    Liu, Dan
    Wei, Haichen
    Lu, Ke
    He, Qiang
    Xie, Linna
    Ma, Ji
    Qiu, Lugui
    Li, Zengjun
    BLOOD, 2024, 144 : 6307 - 6308
  • [46] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul J.
    Koenig, Patricia A.
    Inwards, David J.
    Shah, Keith
    Ziesmer, Steven C.
    Feldman, Andrew L.
    Rao, Radha
    Gupta, Mamta
    Erlichman, Charles
    Witzig, Thomas E.
    LANCET ONCOLOGY, 2011, 12 (04) : 361 - 368
  • [47] Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL)
    Reiter, A.
    Meinhardt, A.
    Burkhardt, B.
    Zimmermann, M.
    Borkhardt, A.
    Kontny, U.
    Mann, G.
    Schrappe, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : CP50 - CP50
  • [48] Lenalidomide (Len) in combination with rituximab (R) demonstrated early evidence of efficacy in a phase I/II study in relapsed/refractory mantle cell lymphoma (MCL)
    Wang, Michael
    Fayad, Luis
    Hagemeister, Frederick
    Neelapu, Sattva
    Samuels, Barry
    Samanigo, Felipe
    Pro, Barbara
    Yi, Qing
    Bell, Neda
    Byrne, Catriona
    Weaver, Pam
    Hartig, Kim
    Knight, Robert
    Zeldis, Jerry
    Kwak, Larry
    Romaguera, Jorge
    BLOOD, 2007, 110 (11) : 755A - 755A
  • [49] Bystander vaccine therapy in mantle cell lymphoma (MCL): Phase II clinical results
    Shah, B. D.
    Tao, J.
    Sokol, L.
    Chervenick, P. A.
    Tomblyn, M. R.
    Pinilla-Ibarz, J.
    Moscinski, L.
    Antonia, S.
    Sotomayor, E. M.
    Dessureault, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation
    Klener, Pavel
    Salek, David
    Pytlik, Robert
    Mocikova, Heidi
    Forsterova, Kristina
    Blahovcova, Petra
    Campr, Vit
    Prochazka, Vit
    Obr, Ales
    Jaksa, Radek
    Kuntscherova, Jana
    Boudova, Ludmila
    Kodet, Roman
    Janikova, Andrea
    Trneny, Marek
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (02) : E50 - E53
12345